The human papillomavirus (HPV) has been clearly established as the primary cause of cervical cancer in nearly all cases [1]. Thus, it should not be surprising that testing for HPV should have a role in measures aimed at control of this disease. The ultimate goal must be eradication of HPV by vaccination, but a more immediate prospect is to utilize the detection and monitoring of the virus as part of the screening and diagnostic process Testing for HPV could have three potential roles' triage of patients with atypical squamous cells of undetermined significance (ASCUS) and low-grade cervical smears; surveillance of high-grade cervical mtraepithehal neoplasia and localised (micro) invasive disease after treatment, and as a primary screening test -either alone or in combination with cytology.
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There is little doubt that well organised cytology-based screening programmes which achieve high compliance and good quality control have been effective in saving lives This has been well documented in Scandinavia and Scotland, and the recent downward mortality trend in England and Wales [2] [3] [4] indicates that the changes to the programme which occurred around 1988 also produced positive results However, a programme based on solely conventional cytology has important limitations In places where screening was properly implemented initially in the 1960s, mortality has dropped by 50%-70% but is now stable, suggesting that the limits of effectiveness have been reached [5] . An audit of the UK programme [6] found that 47% of the fully invasive cancers (l e , ignoring micro-invasive disease) in women under the age of 70 years occurred in individuals with an apparently adequate screening history. A further 11% had abnormalities reported on cytology, but were not diagnosed with cancer until at least six months (and often several years) later.
An ideal screening test should be performed infrequently and be capable of detecting high-grade precursor lesions or early micro-invasive cancers with great accuracy.
In many studies where other tests have also been employed to refer women with negative smears for colposcopy, sensitivities for cytology of only 50%-80% for high grade cervical intraepithelial neoplasia (CIN) have been reported [7] [8] [9] . Also cytological screening is ineffective for adenocarcinoma, which is rapidly accounting for a larger fraction of cancers [10] . The tediousness of the job of the cyto-screener must also be acknowledged, and the regularity with which scandals appear in the popular press highlights all of these weaknesses.
Cytology not only has problems with sensitivity but also specificity Screening is drowning in the 'dysplasia swamp' of borderline and mildly dyskaryotic smears, where the yield of high grade pathology is low and the cost of referral and follow-up is enormous. The UK programme is currently estimated to cost about £ 130 m a year [11] and estimates of $6 billion annually have been made for cervical screening in the United States [12] .
Improvements in cytology via thin-layer preparations and automated screening are likely to improve performance to some extent, but this will be at considerable expense, and I believe that a new approach, more closely related to the underlying process of cervical carcinogenesis, is likely to be the best way forward. Detection of the human papilloma virus (HPV) offers such an approach
The most clearly established role for HPV testing is in the triage of women with borderline or low grade cytological abnormalities (Table 1 ) Early studies have established that HPV testing has discriminatory power in women with abnormal smears that was typically better than that obtained from a repeat smear [8, 9, 13] Subsequent studies have focussed on this particular group have found a very high sensitivity and reasonable specificity for borderline (ASCUS) smears [14] [15] [16] [17] . However, the ALTS study suggested that for LSIL (mild/ moderate) smears the HPV positivity rate was too high and the specificity was too low to justify additional testing. In particular 83% of such women were found to be positive for high risk HPV types, so that few women could be spared immediate colposcopy on the basis of HPV negativity. These data have led the UK Health Technology Assessment panel to recommend a careful, controlled introduction of HPV testing for borderline or [18] , and pilot studies are currently underway in three districts. A number of logistic issues are important here for determining a cost-effective implementation of this approach. If liquid-based cytology is used, then HPV testing can be done as required on the remaining material However, liquid-based sampling is currently an expensive addition to cytology, which itself has yet to prove its cost-effectiveness. The other options of routinely taking a second sample for HPV testing or recalling the 5%-10% of women with low grade cytological abnormalities for a second test are not optimal either, and one would hope a cheap liquid-based approach will be developed which will cater both for the needs of HPV testing and cytology.
It is as a primary screening testing, though, where HPV testing offers the greatest promise, but also where the greatest uncertainties lie. Several studies have shown sensitivities of approximately 90% or greater for the second-generation Hybrid Capture HPV test or consensus primer PCR tests and comparative studies indicate a higher sensitivity than that achieved by cytology [19] [20] [21] [22] (Table 2 ) Specificity is now the major concern and false-positive rates of 5% to 20% have been reported Sensitivity appears to be high regardless of age, but false-positive rates are higher in younger women suggesting that HPV is likely to be more cost-effective in older women Persistence is a key attribute of infections related to high-grade disease. This can currently only be directly verified by repeated testing. Transient infections are much more common in younger women, and restricting HPV testing to women over age 30 (at least for primary screening) substantially reduces the false positive rate from about 15%-20% to about 5% or less.
One way to use HPV testing is as an adjunct to cytology to improve sensitivity This is only viable in older women (above the age of 30 or 35), and even if done infrequently (every 5-10 years), could make an First generation Hybrid Capture Tube test used important contribution in dealing with the increasing large proportion of women who develop cancer after apparently normal cytology smears [6] . By detecting more abnormalities at each screen, it also could allow the screening interval to be safely extended to five years or longer in women who are both cytologically and HPV-negative. Studies of archival smears show that HPV is detectable many years before cancer [23, 24] . Thus, screening failures are more often due to the failure to collect or identify the abnormal cells on the smears than to rapidly developing disease that development de novo in less than five years A more radical approach is to employ HPV as the sole primary test, and then do cytology only on HPVpositive women to determine appropriate management. The very high sensitivity of HPV testing makes this a logical option, even for younger women. As the HPV test is automatable, the more tedious cytological review of smears could be focussed on the few women who are HPV-positive (typically 5% over the age of 35 and 15%-20% in younger women). A key issue here is cost -high volume HPV testing needs to be no more expensive than cytology for this to be viable. A second issue is the appropriate management of HPV-positive but cytology negative women. A substantial fraction of the younger women (15%) will fall into this group, and at least for them, re-testing at one year, at which time most of the HPV infections will have disappeared, seems the most sensible option. Women with HPV DNA persisting for at least one year are likely to have a significant lesion and probably should be referred for colposcopy regardless of the cytological result. Similar issues arise in women with borderline or mild lesions, which in many cases reflect HPV infections that are transient and will resolve spontaneously within one year.
Additionally, HPV testing offers scope for better follow-up of women who have been treated for CIN. Currently, these women receive annual smears for at least five years and often for the rest of their life. Several reports suggest that the persistence of HPV positivity after treatment is an accurate method of assessing treatment failures and could be used to safely return negative women to positive screening after a single follow-up [25, 26] . This could be yet another way in which HPV testing improves the management for women with cervical abnormalities.
When considering the most appropriate role for HPV testing, it must be recognised this will be highly dependent on the existing screening infrastructure For clinical settings in which an effective, well-organised, cytology-based program is in place, the issue is whether HPV testing adds to the existing program and questions of cost-effectiveness, quality control, and added value to current practice come to the fore. In contrast, for settings such commonly found in the developing world, where screening is non-existent or is ineffective because of poor-quality cytology or inherent limitations due to a high rate of inflammatory smears, the more basic questions of sensitivity, specificity cost, and simplicity of testing procedures become paramount. Here it may make more sense to consider infrequent HPV testing, possibly coupled with visual inspection, than to try to make cytology work.
HPV testing also has the potential for being performed on a self-collected sample taken at home To date, most studies have shown that these samples are not as good as physician or nurse taken samples, but they are still at least as sensitive as routine cytological smears [27] . However, better collection devices may provide samples with sensitivities as good as obtaining medical personnel [28] . An accurate self-sampled HPV test could have enormous implications Such a test opens up the possibility of evaluating women who are otherwise unwilling or unable to submit to pelvic examinations. For developing countries, it is not clear if this would offer an advantage over the use of a trained nurse who performs visual inspection and HPV testing in the community. In areas where organised screening is in place, self-sampling offers an additional approach for reaching women who refuse to have conventional screening and also may have a role in surveillance or the monitoring after the treatment of HPV-positive cytology-negative women, in which follow-up testing at short intervals is needed A clear priority is to determine the reasons for lower sensitivity (such as use of a vaginal swab) and to find ways to make a self-sampled test as good as a test performed by a clinician.
The discovery of the central role of HPV in cervical carcinogenesis is just beginning to lead to its use in controlling the disease. Initial results show great promise, but more studies are urgently needed to fully define its role in primary screening A full evaluation of HPV testing should provide information on the length of protection of a negative result and ideally demonstrate a reduction in cancer incidence. This is likely to require a study (or studies) involving several hundred thousand women and a cluster randomised pilot programme would seem to be the most appropriate way of achieving this. The Pap test has served us well since its development and introduction more than 70 years ago However, it is time now to embrace the new advances in disease understanding and diagnostic methodology, and to undertake the most effective ambitious large-scale projects and trials aimed at determining overall approach for controlling cervical cancer 
